[Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?]. / Neo- oder adjuvante Chemotherapie beim Harnblasenkarzinom?
Aktuelle Urol
; 46(3): 242-7, 2015 May.
Article
in De
| MEDLINE
| ID: mdl-26077309
ABSTRACT
Advanced urothelial carcinoma of the bladder is associated with a high metastatic potential. Life expectancy for metastatic patients is poor and rarely exceeds more than one year without further therapy. Neoadjuvant chemotherapy can decrease the tumour burden while reducing the risk of death. Adjuvant chemotherapy has been discussed controversially. Patients with lymph node-positive metastases seem to benefit the most from adjuvant chemotherapy. In selected patients, metastasectomy can prolong survival. In metastastic patients, the combination of gemcitabine and cisplatin has become the new standard regimen due to a lower toxicity in comparison to the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). For second-line treatment, vinflunine is the only approved therapeutic agent.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Urinary Bladder Neoplasms
/
Carcinoma, Transitional Cell
/
Chemotherapy, Adjuvant
/
Neoadjuvant Therapy
Limits:
Humans
Language:
De
Journal:
Aktuelle Urol
Year:
2015
Document type:
Article